Despite numerous efforts to target EGFR, commonly dysregulated in GBM, targeted therapeutic approaches against EGFR have not achieved the same degree of success as seen in other tumour types, particularly when compared to non-small cell lung cancer (NSCLC) [4,5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.